WSWangpan Jackson Shi

Wangpan Jackson Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wangpan Jackson Shi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy

    by Wangpan Jackson Shi, Huan-You Wang

    Although chimeric antigen receptor (CAR) T-cell therapy provides a potential cure for patients with non-Hodgkin B-cell lymphomas/leukemias and plasma cell myelomas, rare reports of the development of T-cell lymphomas (TCLs) in these patients have raised serious safety concerns regarding whether CAR T-cell therapy could directly contribute to the development of TCLs in a specific patient or in patients with certain types of underlying hematologic malignancies. This review aims to comprehensively evaluate the clinicodemographic features, types of TCLs, immunophenotypic characteristics, mutational profiles, and CAR T-cell transgene expression status within the lymphoma cells, as well as explore the underlying mechanisms of lymphomagenesis. A special focus is placed on the interplay between preexisting clonal hematopoiesis, immune dysregulation, and reported genomic alterations that may predispose to and/or drive T-cell lymphomagenesis. Among the total 18 reported cases, TCLs developed in patients with all types of underlying hematologic malignancies and occurred after treatment with all types of widely used commercial CAR T-cell products. Most TCLs showed aberrant T-cell phenotypes according to CD4 and/or CD8 expression. The infused CAR T-cell transgene in lymphoma cells was detected in 63% (10/16) of cases, and 73% (8/11) of cases showed the integration of the CAR transgene into a known tumor suppressor gene or oncogene. At the molecular genomic level, mutations involved in epigenetic regulators (TET2 and DNMT3A) and JAK-STAT signaling pathway, especially JAK3 mutation, were often detected. The potential mechanisms of T-cell lymphomagenesis were complex and multifactorial, including but not limited to preexisting clonal hematopoiesis of indeterminate potential, malignant transformation of CAR T cells, and lymphodepletion chemotherapy.


  • Open Access

    Fibrosarcoma of bone masquerading as fibrous dysplasia: diagnostic pitfall and molecular correlates of aggressive behavior

    by Wangpan J. Shi, Brady K. Huang, Li Lei

    Low-grade fibro-osseous lesions can be challenging to classify. A 33-year-old man presented with synchronous lesions involving the ilium and T2 vertebra. Because of an impending pathologic fracture, he received several doses of denosumab. Initial biopsies showed bland fibro-osseous lesions lacking GNAS or MDM2 alterations and were favored to represent polyostotic fibrous dysplasia. Subsequent iliac curettage revealed a fascicular spindle cell proliferation with subtle atypia and focal ossification, leading to a revised diagnosis of low-grade fibrosarcoma. Re-biopsy of the T2 lesion demonstrated a similar spindle cell proliferation without ossification. Sequencing identified copy number gains involving KIT, PDGFRA, and TERT. At 16-month follow-up, two metastatic pulmonary nodules developed, one responsive to chemotherapy. The patient remains alive with disease at 27 months after presentation. This case highlights a diagnostic pitfall in which low-grade fibrosarcoma with denosumab-associated ossification may mimic fibrous dysplasia and underscores the prognostic value of molecular profiling beyond histologic grading.

  • Open Access

    A unique presentation of multiple synchronous tumors in a patient with POT1 tumor predisposition syndrome

    by Wangpan Shi, Mitchell Zhao, Dong Ren, Frederick Millard, Jason K. Sicklick, Haiyan Zhang

  • Open Access

    The significance of papillary architecture in the follow-up biopsies of patients with progestin-treated atypical endometrial hyperplasia

    by Wangpan J. Shi, Oluwole Fadare

    Follow-up biopsies in patients with progestin-treated atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN) may show papillary structures, the significance of which is unclear. The authors reviewed 253 serial specimens of 84 consecutive patients diagnosed with AH/EIN, inclusive of each patient's pre-progestin treatment sample and all post-treatment specimens. We assessed the predictive relationship between papillary architecture in a post-treatment biopsy and two study outcomes: AH/EIN or carcinoma in at least one sample subsequent to the one in which papillae were identified, and/or the last specimen received for that patient. Papillae were identified in only 51.5% of pre-treatment samples but were present in at least one subsequent post-treatment sample for all patients. Post-treatment samples that exhibited papillae and no glandular crowding were associated with AH/EIN in at least one subsequent specimen in 39.7% (29/73) of cases, compared to 24.0% (6/25) in samples with neither papillae nor glandular crowding (p = .227) and 64.0% (16/25) in samples with concurrent gland crowding and papillae (p = .048). Univariate logistic regression analyses showed that the presence of papillae was not associated with study outcomes (odds ratio [OR], 0.99; 95% confidence interval [CI], 0.49 to 1.99; p = .985), as compared with gland crowding (OR, 1.54; 95% CI, 1.04 to 2.27; p = .031), or concurrent papillae and gland crowding (OR, 2.36; 95% CI, 1.01 to 5.52; p = .048). In post-treatment samples of progestin-treated AH/EIN, the presence of papillary architecture was not demonstrably associated with study outcomes independent of gland crowding, although the concurrent presence of both features may be significantly predictive.